A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage I-III colon cancer
A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage I-III colon cancer
复制标题
基于肿瘤微环境基因的强大面板，用于 I-III 期结肠癌的预后预测和定制治疗
DOI：
10.1016/j.ebiom.2019.03.043
复制
发表时间：
2019-04-01
期刊：
影响因子：
11.1
通讯作者：
Liao, Wangjun
中科院分区：
文献类型：
--
作者：
Zhou, Rui;Zeng, Dongqiang;Liao, Wangjun
背景：肿瘤微环境（TME）对肿瘤的发生发展和治疗至关重要。本研究的目的是发展一个强大的预后模型的基础上TME相关genes.Methods：五个公共微阵列数据集提供临床信息。最小的绝对收缩和选择算子回归方法被用来减少通过bootstrap方法确定的强大的预后基因的维数。结果：我们建立了一个预后面板，指定为肿瘤微环境风险评分（TMRS），由100个基因。使用特定的风险评分公式，TMRS小组通过单变量和多变量分析具有很强的预测无复发生存期和总生存期的能力。与TNM分期相比，TMRS诊断的准确性更高。进一步分析显示，TMRS评分较高的患者未表现出辅助化疗的治疗获益，这可能是由于基质相关通路的激活和基质细胞的浸润。除结肠癌外，TMRS组也被发现是胃癌预后预测和化疗决策的可靠工具。它在预测免疫治疗结果的价值也证实了在其他两个队列组成的转移性尿路上皮癌患者和黑色素瘤patients.Interpretation：我们的TMRS面板可能是一个有效的工具，生存预测和治疗指导患者的I-III期结肠癌。(C)2019年，任作家。由爱思唯尔公司出版
Background: Tumour microenvironment (TME) is critical for the regulation of cancer development as well as therapy. The objective of the current study was the development of a robust prognostic model based on TME-relevant genes.Methods: Five public microarray datasets providing clinical information were obtained. The least absolute shrinkage and selection operator regression method was used to reduce the dimensionality of robust prognostic genes identified via the bootstrap method.Findings: We established a prognostic panel, designated as tumour microenvironment risk score (TMRS), consisting of 100 genes. With specific risk score formulae, the TMRS panel possesses a strong ability to predict relapse-free survival and overall survival through both univariate and multivariate analyses. Compared with the TNM stage, the TMRS panel showed much higher predictive accuracy. Further analysis revealed that patients with higher TMRS scores exhibited no therapeutic benefits from adjuvant chemotherapy, probably due to the activation of stromal relevant pathways and infiltration of stromal cells. Besides colon cancer, the TMRS panel was also revealed to be a reliable tool for prognostic prediction and chemotherapeutic decision-making in gastric cancer. Its value in predicting immunotherapy outcomes was also confirmed in two other cohorts consisting of metastatic urothelial carcinoma patients and melanoma patients.Interpretation: Our TMRS panel may be an effective tool for survival prediction and treatment guidance in patients with stage I-III colon cancer. (C) 2019 The Authors. Published by Elsevier B.V.